

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE
SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
 Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 Definitive Proxy Statement
 Definitive Additional Materials
 Soliciting Material under §240.14a-12

TILRAY, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
 Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11
(set forth the amount on which the filing fee is calculated and state how it was determined)

4) Proposed maximum aggregate value of transaction:

5) Total fee paid:

- Fee paid previously with preliminary materials.
 Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

1) Amount Previously Paid:

2) Form, Schedule or Registration Statement No.:

3) Filing Party:

4) Date Filed:

This Schedule 14A filing consists of the following communications (the “Communications”) from Tilray, Inc., a Delaware corporation (“Tilray”) to its stockholders, relating to Tilray’s Special Meeting of Stockholders originally scheduled to be held on July 29, 2021, subsequently adjourned to August 19, 2021, and further adjourned to September 10, 2021. **This Schedule 14A should be read in conjunction with the proxy statement filed with the U.S. Securities and Exchange Commission on or about June 25, 2021.**

The Communications were first used or made available to Tilray’s stockholders on August 20, 2021.

Attention Shareholders

Flexibility for Our Operations, Not Dilution of Our Shareholders

Vote FOR Proposal 1



Proposal 1 WILL NOT by itself dilute our shareholders or increase our number of outstanding shares.

What it will do is enable us to move quickly to take advantage of opportunities we believe are aligned with our growth strategy and that can create real, long-term shareholder value.

[VOTE FOR PROPOSAL 1 »](#)

A vote FOR Proposal 1



Will not lead to automatic dilution



Will allow Tilray to optimize the execution of the MedMen transaction



Will give Tilray the flexibility to pursue acquisitions to accelerate our growth



Will allow Tilray to raise additional capital to enhance research, cultivation and distribution capabilities

How To Vote "FOR" Proposal 1

Your vote is critical no matter how many or how few shares you own.

Please vote today. Voting is quick and easy.

Already voted? Only your latest-dated vote counts. Cast your vote today "FOR" Proposal 1.



Vote By Internet

1. Locate the control number on your Voting Instruction Form
2. If your control number is 16 digits: log on to www.proxyvote.com, OR if your control number is 12 digits: log on to www.proxypush.com
3. Simply enter your control number to vote.



Vote by Phone

1. Locate the control number on your Voting Instruction Form
2. If your control number is 16 digits, dial [1-800-454-8683](tel:1-800-454-8683) toll-free, OR if your control number is 12 digits, dial toll-free [1-866-586-3109](tel:1-866-586-3109)
3. Simply enter your control number on your phone keypad to vote.



Vote by Mail

Mark, sign and date your proxy card or voting instruction form and return it in the postage-paid envelope provided

If you have any questions, or need any assistance in voting your shares, please contact Morrow

Sodali LLC at [\(833\) 497-7395](tel:8334977395) toll-free in the U.S. and Canada, or by email at

TLRY@info.morrowsodali.com.



Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Tilray Shareholders Vote "FOR" All Proposals at Tilray's Upcoming Special Meeting

Tilray urges shareholders to vote today in support of long-term value creation

Sign up with your email address to receive news and updates.

Email Address

SIGN UP



Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the need for an increase in authorized shares of common stock from 743,333,333 shares to 990,000,000 shares and the potential negative impacts to the company if the corresponding proposal is not approved. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Aphria and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.

[Accept](#) [Decline](#)

Attention Shareholders

Help Maximize Our Potential to Create Value for Shareholders Through the MedMen Transaction

Vote FOR Proposal 1



Tilray is focused on building the world's leading cannabis-focused consumer product goods company with a goal of \$4 billion in revenue by the end of our fiscal 2024.

Our purchase of MedMen convertible notes is a critical step towards our objective of leading the U.S. cannabis market when legalization allows.

The passage of Proposal 1 will enable Tilray to maximize the potential to create shareholder value through the MedMen transaction.

[VOTE FOR PROPOSAL 1 »](#)

A vote FOR Proposal 1:



Allows Tilray to optimize the execution of the MedMen transaction, which will accelerate our ability to capitalize on the opportunity of the \$80 billion U.S. cannabis market upon federal legalization.



Gives Tilray the flexibility to pursue acquisitions to accelerate our growth.



Allows Tilray to raise additional capital to

How To Vote "FOR" Proposal 1

Your vote is critical no matter how many or how few shares you own.

Please vote today. Voting is quick and easy.

Already voted? Only your latest-dated vote counts. Cast your vote today "FOR" Proposal 1.



Vote By Internet

1. Locate the control number on your Voting Instruction Form
2. If your control number is 16 digits: log on to www.proxyvote.com, OR if your control number is 12 digits: log on to www.proxypush.com
3. Simply enter your control number to vote.



Vote by Phone

1. Locate the control number on your Voting Instruction Form
2. If your control number is 16 digits, dial 1-800-454-8683 toll-free, OR if your control number is 12 digits, dial toll-free 1-866-586-3109
3. Simply enter your control number on your phone keypad to vote.



Vote by Mail

Mark, sign and date your proxy card or voting instruction form and return it in the postage-paid envelope provided

If you have any questions, or need any assistance in voting your shares, please contact Morrow Sodali LLC at [\(833\) 497-7395](tel:8334977395) toll-free in the U.S. and Canada, or by email at TLRY@info.morrowsodali.com.



Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Tilray Shareholders Vote "FOR" All Proposals at Tilray's Upcoming Special Meeting

Tilray urges shareholders to vote today in support of long-term value creation

Email Address

SIGN UP



©2021 Tilray. All Rights Reserved. [Privacy Policy](#) | [Terms of Use](#).

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the need for an increase in authorized shares of common stock from 743,333,333 shares to 990,000,000 shares and the potential negative impacts to the company if the corresponding proposal is not approved. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Aphria and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.

Accept Decline

Attention Shareholders

Help Tilray Grow

Vote FOR Proposal 1



The passage of Proposal 1 will enable Tilray to optimize the execution of our acquisition of MedMen convertible notes and potentially accelerate our path into the U.S. market upon federal legalization.

Our industry is dynamic and expanding rapidly and passage of Proposal 1 will provide important flexibility to pursue attractive acquisitions to maximize shareholder value.

[VOTE FOR PROPOSAL 1 »](#)

Proposal 1 would enable Tilray to seize attractive opportunities to create shareholder value, including:



Optimizing the execution of the MedMen transaction, which will accelerate our ability to capitalize on the opportunity of the \$80 billion U.S. market upon federal legalization



Making smaller acquisitions to accelerate our expansion into innovative new products and attractive markets



Pursuing larger acquisitions, which would require separate shareholder approval



Raising additional capital to enhance our research, cultivation and distribution capabilities

How To Vote FOR Proposal 1

Your support is critical no matter how many or how few shares you own.

Please vote today. Voting is quick and easy.

Already voted? Only your latest-dated vote counts. Cast your vote "FOR" Proposal 1.



Vote by Internet

1. Locate the control number on your Voting Instruction Form
2. If your control number is 16 digits: log on to www.proxyvote.com, OR if your control number is 12 digits: log on to www.proxypush.com
3. Simply enter your control number to vote.



Vote by Phone

1. Locate the control number on your Voting Instruction Form
2. If your control number is 16 digits, dial [1-800-454-8683](tel:1-800-454-8683) toll-free, OR if your control number is 12 digits, dial toll-free [1-866-586-3109](tel:1-866-586-3109)
3. Simply enter your control number on your phone keypad to vote.



Vote by Mail

Mark, sign and date your proxy card or voting instruction form and return it in the postage-paid envelope provided

If you have any questions, or need any assistance in voting your shares, please contact Morrow

Sodali LLC at [\(833\) 497-7395](tel:8334977395) toll-free in the U.S. and Canada, or by email at

TLRY@info.morrowsodali.com.



Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Tilray Shareholders Vote "FOR" All Proposals at Tilray's Upcoming Special Meeting

Tilray urges shareholders to vote today in support of long-term value creation

Sign up with your email address to receive news and updates.



Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, "forward-looking statements") under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the "safe harbor" created by those sections and other applicable laws. Forward-looking statements can be identified by words such as "forecast," "future," "should," "could," "enable," "potential," "contemplate," "believe," "anticipate," "estimate," "plan," "expect," "intend," "may," "project," "will," "would" and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the need for an increase in authorized shares of common stock from 743,333,333 shares to 990,000,000 shares and the potential negative impacts to the company if the corresponding proposal is not approved. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Aphria and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Attention Shareholders

Tilray's Investment in MedMen Creates Tremendous Opportunities

Vote FOR Proposal 1



Tilray is focused on building the world's leading cannabis-focused consumer product goods company with a goal of \$4 billion of revenue by the end of our fiscal 2024.

Our strategic investment in MedMen convertible notes provides us with a potential accelerated path into the \$80 billion U.S. cannabis market upon federal legalization.

The passage of Proposal 1 will enable us to optimize the execution of this transaction to maximize our potential to create value for our shareholders.

[VOTE FOR PROPOSAL 1 »](#)

A vote FOR Proposal 1:



Allows Tilray to optimize the execution of the MedMen transaction, which will accelerate our ability to capitalize on the opportunity of the \$80 billion U.S. cannabis market upon federal legalization.



Gives Tilray the flexibility to pursue acquisitions to accelerate our growth.



Allows Tilray to raise additional capital to enhance research, cultivation and distribution capabilities

How To Vote "FOR" Proposal 1

Your vote is critical no matter how many or how few shares you own.

Please vote today. Voting is quick and easy.

Already voted? Only your latest-dated vote counts. Cast your vote today "FOR" Proposal 1.



Vote By Internet

1. Locate the control number on your Voting Instruction Form
2. If your control number is 16 digits: log on to www.proxyvote.com, OR if your control number is 12 digits: log on to www.proxypush.com
3. Simply enter your control number to vote.



Vote by Phone

1. Locate the control number on your Voting Instruction Form
2. If your control number is 16 digits, dial [1-800-454-8683](tel:1-800-454-8683) toll-free, OR if your control number is 12 digits, dial toll-free [1-866-586-3109](tel:1-866-586-3109)
3. Simply enter your control number on your phone keypad to vote.



Vote by Mail

Mark, sign and date your proxy card or voting instruction form and return it in the postage-paid envelope provided

If you have any questions, or need any assistance in voting your shares, please contact Morrow Sodali LLC at [\(833\) 497-7395](tel:8334977395) toll-free in the U.S. and Canada, or by email at TLRY@info.morrowsodali.com.



Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Tilray Shareholders Vote "FOR" All Proposals at Tilray's Upcoming Special Meeting

Tilray urges shareholders to vote today in support of long-term value creation

Sign up with your email address to receive news and updates.



Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the need for an increase in authorized shares of common stock from 743,333,333 shares to 990,000,000 shares and the potential negative impacts to the company if the corresponding proposal is not approved. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Aphria and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Attention Shareholders

Vote to Help Tilray Grow

Vote FOR Proposal 1



The passage of Proposal 1 will enable Tilray to optimize the execution of our acquisition of MedMen convertible notes and potentially accelerate our path into the U.S. cannabis market upon federal legalization.

Our industry is dynamic and expanding rapidly and passage of Proposal 1 will provide important flexibility to pursue attractive acquisitions to maximize shareholder value.

[VOTE FOR PROPOSAL 1 »](#)

Proposal 1 would enable Tilray to seize attractive growth opportunities, including:



Optimizing the execution of the MedMen transaction, which will accelerate our ability to capitalize on the opportunity of the \$80 billion U.S. cannabis market upon federal legalization



Making smaller acquisitions to accelerate our expansion into innovative new products and attractive markets



Pursuing larger acquisitions, which would require separate shareholder approval



Raising additional capital to enhance our research, cultivation and distribution capabilities

How To Vote "FOR" Proposal 1

Your vote is critical no matter how many or how few shares you own.

Please vote today. Voting is quick and easy.

Already voted? Only your latest-dated vote counts. Cast your vote today "FOR" Proposal 1.



Vote By Internet

1. Locate the control number on your Voting Instruction Form
2. If your control number is 16 digits: log on to www.proxyvote.com, OR if your control number is 12 digits: log on to www.proxypush.com
3. Simply enter your control number to vote.



Vote by Phone

1. Locate the control number on your Voting Instruction Form
2. If your control number is 16 digits, dial [1-800-454-8683](tel:1-800-454-8683) toll-free, OR if your control number is 12 digits, dial toll-free [1-866-586-3109](tel:1-866-586-3109)
3. Simply enter your control number on your phone keypad to vote.



Vote by Mail

Mark, sign and date your proxy card or voting instruction form and return it in the postage-paid envelope provided

If you have any questions, or need any assistance in voting your shares, please contact Morrow Sodali LLC at [\(833\) 497-7395](tel:8334977395) toll-free in the U.S. and Canada, or by email at TLRY@info.morrowsodali.com.



Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Tilray Shareholders Vote "FOR" All Proposals at Tilray's Upcoming Special Meeting

Tilray urges shareholders to vote today in support of long-term value creation

Sign up with your email address to receive news and updates.



©2021 Tilray. All Rights Reserved. [Privacy Policy](#) | [Terms of Use](#).

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, "forward-looking statements") under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the "safe harbor" created by those sections and other applicable laws. Forward-looking statements can be identified by words such as "forecast," "future," "should," "could," "enable," "potential," "contemplate," "believe," "anticipate," "estimate," "plan," "expect," "intend," "may," "project," "will," "would" and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the need for an increase in authorized shares of common stock from 743,333,333 shares to 990,000,000 shares and the potential negative impacts to the company if the corresponding proposal is not approved. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Aphria and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.

Accept Decline



Attention Shareholders

We've made voting FOR Proposal 1 easy for all shareholders

Vote FOR Proposal 1



Make your voice heard by voting FOR Proposal 1 to enable Tilray to maximize our potential to create substantial value for our shareholders.

You can vote FOR Proposal 1 online or by phone.

Online, all you need to do is find the Control Number on your proxy card or voting instruction form, log in to the designated voting site and follow the instructions provided. If you prefer to vote by phone, you just need to find the Control Number on your proxy card or voting instruction form, dial the designated telephone number and follow the instructions provided.

[VOTE FOR PROPOSAL 1 »](#)

How To Vote "FOR" Proposal 1

Your vote is critical no matter how many or how few shares you own.


Please vote today. Voting is quick and easy.

Already voted? Only your latest-dated vote counts. Cast your vote today "FOR" Proposal 1.



Vote By Internet

1. Locate the control number on your Voting Instruction Form
2. If your control number is 16 digits: log on to www.proxyvote.com, OR if your control number is 12 digits: log on to www.proxypush.com
3. Simply enter your control number to vote.



Vote by Phone

1. Locate the control number on your Voting Instruction Form
2. If your control number is 16 digits, dial [1-800-454-8683](tel:1-800-454-8683) toll-free, OR if your control number is 12 digits, dial toll-free [1-866-586-3109](tel:1-866-586-3109)
3. Simply enter your control number on your phone keypad to vote.



Vote by Mail

Mark, sign and date your proxy card or voting instruction form and return it in the postage-paid envelope provided

If you have any questions, or need any assistance in voting your shares, please contact Morrow Sodali LLC at [\(833\) 497-7395](tel:8334977395) toll-free in the U.S. and Canada, or by email at TLRY@info.morrowsodali.com.



Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Tilray Shareholders Vote "FOR" All Proposals at Tilray's Upcoming Special Meeting

Tilray urges shareholders to vote today in support of long-term value creation

Sign up with your email address to receive news and updates.



©2021 Tilray. All Rights Reserved. [Privacy Policy](#) | [Terms of Use](#).

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, "forward-looking statements")

under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the need for an increase in authorized shares of common stock from 743,333,333 shares to 990,000,000 shares and the potential negative impacts to the company if the corresponding proposal is not approved. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Aphria and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.

[Accept](#) [Decline](#)



Tilray Investor Relations

3 followers
Promoted



\$TLRY shareholders - have you cast your vote FOR Proposal 1? We need your vote to take advantage of the growth opportunities in our market. Your vote is critical no matter how many or how few shares you own.



Be The Difference Maker - #VoteForProposal1

[Learn more](#)

tilrayshareholders.com



Tilray Investor Relations

3 followers

Promoted



Our goal is to create long lasting value for all \$TLRY shareholders. Supporting Proposal 1 will help us capitalize on substantial growth opportunities, pursue additional attractive acquisitions and enhance research, cultivation and distribution capabilities.



Growth Opportunities for Lasting Value

[Learn more](#)

tilrayshareholders.com



Tilray Investor Relations

3 followers

Promoted



Proposal 1 WILL NOT lead to automatic dilution. Similar efforts in the past have added flexibility to our acquisition strategy and helped us raise capital to enhance our operations.

FLEXIBILITY
for our operations,
NOT DILUTION
of our
shareholders



Flexibility Not Dilution - #VoteForProposal1

[Learn more](#)

tilrayshareholders.com



Tilray Investor Relations

3 followers

Promoted



The \$TLRY purchase of MedMen convertible notes positions us to become a leading player in the US marketplace. Every vote counts!

[#BeTheDifferenceMaker](#)

Maximize value for
SHAREHOLDERS
through the
MEDMEN
transaction



Every Vote Counts! [#VoteForProposal1](#)

[Learn more](#)

tilrayshareholders.com



Tilray Investor Relations

3 followers

Promoted



A vote FOR on Proposal 1 will allow \$TLRY to invest in MedMen and expand its strategic footprint among the retail market in the U.S. A tremendous growth opportunity for \$TLRY!

EXPANDING
our footprint in the
LARGE US
MARKET
is our goal



We Need Your Vote - #VoteForProposal1

[Learn more](#)

tilrayshareholders.com



Tilray Investor Relations

3 followers

Promoted



\$TLRY is focused on building the world's leading industry-focused consumer-branded company with a goal of \$4 billion in revenue by the end of our fiscal 2024. Vote FOR Proposal 1!

**Vote FOR
to
ACCELERATE
our growth plans**



Be The Difference Maker - #VoteForProposal1

[Learn more](#)

tilrayshareholders.com




Tilray Investor Relations

3 followers

Promoted



Thank you to all of our shareholders who have already voted FOR Proposal 1. If you haven't voted, make your voice heard by voting FOR Proposal 1 to enable Tilray to maximize our potential to create substantial value for our shareholders. Vote by phone or online.



Voting is Easy #VoteForProposal1

[Learn more](#)

tilrayshareholders.com



Tilray Investor Relations

3 followers

Promoted



Our strategic investment in MedMen convertible notes provides us with a potential accelerated path into the \$80B U.S. cannabis market upon federal legalization. A vote FOR Proposal 1 allows Tilray to raise capital to enhance research, cultivation and distribution capabilities.

Tilray's Investment in

MEDMEN

Creates

TREMENDOUS OPPORTUNITIES



Legalization is Coming in the US

[Learn more](#)

tilrayshareholders.com



tilrayir

Help Tilray

GROW



TILRAY®



tilrayir #TLRY shareholders - have you cast your vote FOR Proposal 1? We need your vote to take advantage of the growth opportunities in our market. Your vote is critical no matter how many or how few shares you own. See link in bio for

more information.

Long term
GROWTH
leads to
**LONG
LASTING**
shareholder value



tilrayir Our goal is to create long lasting value for all \$TLRY shareholders. Supporting Proposal 1 will help us capitalize on substantial growth opportunities, pursue additional attractive acquisitions and enhance research, cultivation and distribution capabilities. See link in bio for

and distribution capabilities. See [link in bio](#) for more information.



tilrayir

FLEXIBILITY
for our operations,
NOT
DILUTION
of our
shareholders



TILRAY



tilrayir Proposal 1 WILL NOT lead to automatic dilution. Similar efforts in the past have added flexibility to our acquisition strategy and helped us raise capital to enhance our operations. See link in bio for more information.





tilrayir

Maximize value for **SHAREHOLDERS** through the **MEDMEN** transaction



tilrayir The \$TLRY purchase of MedMen convertible notes positions us to become a leading player in the US marketplace. Every vote counts! **#BeTheDifferenceMaker** See link in bio for more information.



EXPANDING
our footprint in the
LARGE US
MARKET
is our goal



tilrayir A vote FOR on Proposal 1 will allow \$TLRY to invest in MedMen and expand its strategic footprint among the retail market in the U.S. A tremendous growth opportunity for \$TLRY! See link in bio for more information.



Vote FOR
to
ACCELERATE
our growth plans



tilrayir #TLRY is focused on building the world's leading industry-focused consumer-branded company with a goal of \$4 billion in revenue by the end of our fiscal 2024. Vote FOR Proposal 1! See link in bio for more information.





tilrayir

We've made
voting
FOR
easy



TILRAY®



tilrayir Thank you to all of our shareholders who have already voted FOR Proposal 1. If you haven't voted, make your voice heard by voting FOR Proposal 1 to enable Tilray to maximize our potential to create substantial value for our shareholders. Vote by phone or online. See link in

shareholders. vote by phone or online. see link in bio for more information.

Tilray's Investment in **MEDMEN** Creates **TREMENDOUS OPPORTUNITIES**



tilrayir Our strategic investment in MedMen convertible notes provides us with a potential accelerated path into the \$80B U.S. cannabis market upon federal legalization. A vote FOR Proposal 1 allows Tilray to raise capital to enhance research, cultivation and distribution

capabilities. See link in bio for more information.

**ATTENTION
SHAREHOLDERS:**

VOTE "FOR"

**INCREASED
AUTHORIZED SHARES**



**ATTENTION
SHAREHOLDERS:**

VOTE "FOR"

**INCREASED
AUTHORIZED SHARES**



**ATTENTION
SHAREHOLDERS:
TAKE ACTION.
VOTE FOR TODAY.
#HELPTILRAYGROW**



**ATTENTION
SHAREHOLDERS:
TAKE ACTION.
VOTE FOR TODAY.
#HELPTILRAYGROW**



ATTENTION SHAREHOLDERS:

VOTE "FOR"

INCREASED AUTHORIZED SHARES



ATTENTION SHAREHOLDERS:

VOTE "FOR"
INCREASED AUTHORIZED SHARES



ATTENTION SHAREHOLDERS:
TAKE ACTION. VOTE FOR TODAY.
#HELPTILRAYGROW



ATTENTION SHAREHOLDERS:

TAKE ACTION. VOTE FOR TODAY.

#HELPTILRAYGROW

